Epsilogen
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
London Manbre Hammersmith Road, Waterfro...Phone Number
+44 2036577612Website
www.epsilogen.comRevenue
$11.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Epsilogen
Epsilogen is a pioneering company specializing in pan-isotype antibody therapeutics for cancer treatment, focusing on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead product, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, targeting folate receptors in platinum-resistant ovarian cancer patients. The company aims to optimize immune responses by matching antibody isotypes to specific cancers and combining them to enhance anti-cancer potential. Epsilogen's innovative approach positions it as a leader in the development of novel cancer therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epsilogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Epsilogen had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Epsilogen has new funding data
Congratulate Masked Content for being promoted to Masked Content at Epsilogen
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Epsilogen recently announced quarterly report
Epsilogen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Epsilogen has recently received funding, and reach out quickly before it becomes old news!
Check out if Epsilogen is spiking on competitors!
Product Launch: Get notified when Epsilogen launches new products
Recommended Actions
Find VP level buyers at Epsilogen
Find 3 more new buyers
Compare Similar Companies to Epsilogen
Compare insights from companies similar to Epsilogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Epsilogen
$11.5M
11-50
Private
$67.8M
2017
N/A
![iito] Business Intelligence Logo](https://res.cloudinary.com/zoominfo-images/image/upload/w_120,h_120,c_fit/life-sciences-europe.com){kind=small}
Company Profile Activity
Activity Insights
Epsilogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Epsilogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Epsilogen.
Epsilogen financials insights
Gather financial insights about Epsilogen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$6.3M
2020
Other Financing Round
$3.9M
2024
Series B
$57.6M
Epsilogen Tech Stack
A closer look at the technologies used by Epsilogen
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Epsilogen
Sign Up For FreeTo access detailed company insights
Epsilogen is a pioneering company specializing in pan-isotype antibody therapeutics for cancer treatment, focusing on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead product, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, targeting folate receptors in platinum-resistant ovarian cancer patients. The company aims to... Read More
